Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702345 | Surgical Oncology | 2017 | 8 Pages |
Abstract
Pancreas cancer surgery should attempt to achieve negative margins of resection with the removal of at least 12 lymph nodes. Hyperthermic intraperitoneal gemcitabine can adequately eradicate malignant cells dislodged from the cancer specimen into the bed of the resection at high density and on distant peritoneal surfaces as peritoneal metastases. Long-term intraperitoneal gemcitabine may act on micrometastases in the liver through absorption into the portal vein blood and the lymph nodes as a result of gemcitabine absorption by subperitoneal lymphatic channels. The use of HIPEC and NIPEC-LT gemcitabine may improve local control of resected pancreas cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paul H. Sugarbaker,